Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

David-Axel Laplaud, MD, PhD, Romain Casey, PhD, Laetitia Barbin, PhD, et al., on behalf of the SFSEP and OFSEP groups

Cite as: Neurology® 2019;93:e635-e646. doi:10.1212/WNL.0000000000007938

Study objective and summary result
This study compared teriflunomide and dimethyl fumarate (DMF) in terms of effectiveness for patients with relapsing-remitting multiple sclerosis (RRMS) in a multicenter French cohort, and it found that teriflunomide and DMF are similar in terms of clinical effectiveness for patients with RRMS.

Classification of evidence
Class III.

What is known and what this paper adds
Teriflunomide and DMF both reduce annualized relapse rates and disability accumulation in patients with RRMS, but no investigation has directly compared them. This investigation shows that they are similar in terms of clinical effectiveness.

Participants and setting
The investigators analyzed data from adults with RRMS who were members of the Observatoire Français de la Sclérose En Plaques cohort (NCT02889965), which was mostly conducted through 34 centers in France. The selected patients began receiving teriflunomide (n = 713) or DMF (n = 1,057) between May 2014 and January 2016 and had Expanded Disability Status Scale (EDSS) scores ≤5.5 at treatment initiation. The data for these analyses were accessed on December 15, 2017.

Design, size, and duration
The main outcomes of interest were relapses within 1 or 2 years of treatment initiation. The investigators also examined from-baseline EDSS score changes within 1 or 2 years of treatment initiation. Logistic regression models were used to compare the outcomes for the teriflunomide-treated and DMF-treated patients, and propensity scores were used to address potential confounders.

Main results and the role of chance
The teriflunomide-treated and DMF-treated groups were similar in terms of 1-year relapse rates (19.4% vs 21.6%, respectively; p = 0.22) and 2-year relapse rates (28.1% vs 30.9%, respectively; p = 0.19). No between-group differences in from-baseline EDSS score changes were observed.

Bias, confounding, and other reasons for caution
This investigation lacked complete data for all patients. Treatments were not randomly assigned.

Generalizability to other populations
The reliance on data from France may limit the international generalizability of the results.

Study funding/potential competing interests
This study was funded by Fondation ARSEP, the Centre Hospitalier Universitaire de Nantes, the Association ANTARES, and the Agence Nationale de la Recherche (French government). Some authors report receiving consulting fees, lecture honoraria, travel and conference expenses, committee appointments, and research support from healthcare companies; serving as investigators on industry-sponsored clinical trials; receiving research support from Rennes University Hospital; and having patents pending. Go to Neurology.org/N for full disclosures.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.

Copyright © 2019 American Academy of Neurology
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
David-Axel Laplaud, Romain Casey, Laetitia Barbin, et al.
Neurology 2019;93;e635-e646 Published Online before print July 12, 2019
DOI 10.1212/WNL.0000000000007938

This information is current as of July 12, 2019

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/93/7/e635.full

References
This article cites 27 articles, 5 of which you can access for free at:
http://n.neurology.org/content/93/7/e635.full#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://n.neurology.org/content/93/7/e635.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Class III
http://n.neurology.org/cgi/collection/class_iii
Clinical trials Observational study (Cohort, Case control)
http://n.neurology.org/cgi/collection/c clinical_trials_observational_study_cohort_case_control
Multiple sclerosis
http://n.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise

Neurology ® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.